Neurological & Neuromuscular
Also called Severe Myoclonic Epilepsy of Infancy, SMEI
Dravet Syndrome represents one of the most severe forms of childhood-onset epilepsy, caused primarily by loss-of-function mutations in the SCN1A gene. This gene encodes the Nav1.
Dravet Syndrome typically manifests between 6 months and 3 years of age, though most commonly around 6-12 months. It affects males and females equally across all ethnic and racial groups. About 80% of cases result from de novo (new) SCN1A mutations, though familial inheritance occurs in approximately 10-20% of cases, often with incomplete penetrance.
Dravet Syndrome research is advancing with FDA-approved medications like stiripentol and cannabidiol showing efficacy, and ongoing trials investigating additional cannabinoid-based treatments, gene therapy approaches, and sodium channel modulators. Clinical trials are also exploring antisense oligonucleotides and other molecular approaches to restore SCN1A function. Specialized epilepsy centers often have access to clinical trial information and can assess eligibility. The Dravet Syndrome Foundation maintains resources on trial availability and treatment approaches.
Duchenne muscular dystrophy is an X-linked genetic disorder causing progressive muscle weakness and degeneration, beginn...
Spinal muscular atrophy is an autosomal recessive genetic disorder affecting motor neurons in the spinal cord, causing p...
Myasthenia gravis is a chronic autoimmune neuromuscular disorder causing muscle weakness and rapid fatigue. Antibodies a...